Kiran Mazumdar-Shaw

Timeline

1. 1953Born on 23 March in Bangalore, now Bengaluru, to Gujarati parents. Her father, Rasendra Mazumdar, was head brewmaster at United Breweries.
2. 1968Graduates from Bishop Cotton Girls' School in Bangalore.
3. 1973Takes a bachelor's degree in zoology from Bangalore University after pre-university study at Mount Carmel College; a hoped for medical school place does not come with a scholarship.
4. 1974Enrols in the malting and brewing course at Ballarat College in Australia, the only woman in her class.
5. 1975Earns the master brewer qualification and tops her class.
6. 1975Works as a trainee brewer at Carlton and United Breweries in Melbourne and as a trainee maltster at Barrett Brothers and Burston.
7. 1976Returns to India and works as a technical consultant at Jupiter Breweries in Calcutta and a technical manager at Standard Maltings in Baroda.
8. 1977Told she cannot be hired as a master brewer in India because brewing is, in the words used to her, a man's work, and begins looking for work abroad.
9. 1978Meets Leslie Auchincloss of Biocon Biochemicals of Cork, Ireland, who wants an Indian partner to produce papain, and agrees to build the venture.
10. 1978Founds Biocon India in the garage of her rented Bengaluru house with 10,000 rupees of seed capital.
11. 1979Biocon begins exporting enzymes to the United States and Europe, the first Indian company to do so.
12. 1984Starts an in house research and development team working on novel enzymes and solid substrate fermentation.
13. 1987ICICI Ventures, through Narayanan Vaghul, backs a venture fund of 250,000 dollars for Biocon's research.
14. 1989Biocon becomes the first Indian biotech company to receive United States funding for proprietary technologies, and she is awarded the Padma Shri.
15. 1990Incorporates Biocon Biopharmaceuticals in a joint venture with the Cuban Center of Molecular Immunology.
16. 1994Sets up Syngene, the contract research subsidiary that serves other drug companies.
17. 1997Unilever sells its specialty chemicals division, including its holding in Biocon, to Imperial Chemical Industries.
18. 1998Marries John Shaw, who raises 2 million dollars to buy Biocon's shares from ICI; she becomes Kiran Mazumdar-Shaw.
19. 2000Sets up Clinigene for clinical research, later merged into Syngene.
20. 2004Biocon lists on the stock market in India's first biotech initial public offering, oversubscribed 33 times and valued at 1.11 billion dollars on the first day; she founds the Biocon Foundation.
21. 2005Awarded the Padma Bhushan and named a Technology Pioneer by the World Economic Forum.
22. 2009Opens a cancer care centre with the Narayana Hrudayalaya group and is awarded the Nikkei Asia Prize.
23. 2014Awarded the Othmer Gold Medal and becomes the first woman to head the board of governors of the Indian Institute of Management Bangalore.
24. 2015Syngene lists on the BSE and NSE, and she joins the Giving Pledge.
25. 2019Elected to the United States National Academy of Engineering, the first Indian woman to be honoured.
26. 2020Named EY World Entrepreneur of the Year.
27. 2022Her husband, John Shaw, dies on 24 October.
28. 2025Forbes ranks her the 93rd wealthiest person in India, with a net worth of 3.42 billion dollars.

Early life and family

Kiran Mazumdar was born on 23 March 1953 in Bangalore, in what is now Karnataka, into a Gujarati family. Her father, Rasendra Mazumdar, was the head brewmaster at United Breweries, the company behind Kingfisher beer, and her mother ran a household that put education before almost everything else. The family was comfortable rather than rich, and the single largest influence on her working life was her father's trade rather than any business the family owned.^[1][5]

She grew up expecting to become a doctor. She studied biology and zoology seriously enough to take a degree in the subject, but the plan failed on money rather than marks: she could not get a scholarship, and without one medical school was out of reach. That disappointment is the hinge of her story, and she has described the moment often, because it is the reason she took her father's suggestion and moved into fermentation science instead.^[1][5]

The family's other inheritance was less comfortable. A woman in Indian brewing in the 1970s had no route into the industry at all, and she would spend the first decade of her career being told that what she had trained to do was not work a woman could do. Her answer was to build her own company rather than to keep asking other people for a job.^[1][6]

Education

She was educated at Bishop Cotton Girls' School in Bangalore, where she graduated in 1968, and then at Mount Carmel College, a women's college affiliated to Bangalore University, where she took the pre-university course. She read biology and zoology and graduated from Bangalore University with a bachelor's degree in zoology in 1973.^[1][5]

Her father suggested fermentation science as a practical alternative to medicine, and in 1974 she went to Ballarat College in Australia to study malting and brewing. She was the only woman enrolled in the brewing course and she topped her class, which is the detail she tends to give when asked whether the industry really was closed to her: the marks were never the problem. She earned the master brewer qualification in 1975.^[1][5]

The training continued on the factory floor as well as in the classroom. She worked as a trainee brewer at Carlton and United Breweries in Melbourne and as a trainee maltster at Barrett Brothers and Burston in Australia, and both were hands on roles in which the science had to survive contact with equipment. What she learned there, she has said, was less a recipe than a way of running a plant: hygiene, consistency, and the discipline of a process that fails quietly if you ignore it.^[1]

Brewing career

She returned to India and worked between 1975 and 1977 as a technical consultant at Jupiter Breweries in Calcutta and as a technical manager at Standard Maltings Corporation in Baroda. When she looked for a permanent position in Bangalore or Delhi she was told, in terms that have been quoted in almost every profile written about her since, that she could not be hired as a master brewer in India because it was a man's work.^[1][6]

Unable to get the job she had trained for, she began looking abroad and was offered a position in Scotland. That offer is what makes the next year of her life decisive: she would have taken it and the story would have ended as a footnote about an Indian woman who brewed beer in Britain. Instead, a chance introduction in 1978 changed the plan.^[1]

Founding Biocon

Before she could leave for Scotland she met Leslie Auchincloss, the founder of Biocon Biochemicals Limited of Cork, Ireland, a company that made enzymes for the brewing, food packaging and textile industries. Auchincloss wanted a partner in India to run an Indian subsidiary that would supply him with papain, an enzyme extracted from papaya. She agreed, on one condition: if she did not want to continue after six months, she would be given a brewmaster's position comparable to the one she was giving up.^[1]

After a short spell as a trainee manager at the Irish company she came back and started Biocon India in 1978 in the garage of her rented house in Bengaluru with a seed capital of 10,000 rupees. It was structured as a joint venture, but Indian law at the time restricted foreign ownership of such a company to 30 per cent, which meant that 70 per cent of it belonged to her. The first employee was a retired garage mechanic, the first unit was a shed of about 280 square metres, and the most complicated piece of equipment in her laboratory was a spectrophotometer.^[1]

The early years were a lesson in credibility. She was young, she was a woman, and the business model was untested in India, so no one would fund it in the ordinary way. A chance meeting with a banker at a social event produced her first real financial backing, and recruiting scientists to a start up in a country with unreliable power, poor quality water and no sterile laboratory infrastructure was close to impossible. She has described building the company as an exercise in solving problems that a Western startup would never see.^[1]

The first products were enzyme extractions: papain from papaya, used to tenderise meat, and isinglass from tropical catfish, used to clarify beer. Within a year of its founding Biocon was manufacturing enzymes and exporting them to the United States and Europe, the first Indian company to do so, and at the end of her first year she used her earnings to buy an eight hectare property on which to expand.^[1]

Biocon and Biocon Biologics

Biocon Limited is the company she founded and still chairs, and it is the largest part of her public identity. From an enzymes business it grew into a fully integrated biopharmaceutical company with a portfolio built around diabetes, oncology and auto immune disease. Two of its claims are unusually concrete: it is Asia's largest producer of insulin, and it operates some of the largest perfusion based antibody production facilities in the world.^[1]

The strategy that carried it there is what she calls affordable innovation. When the patent on the cholesterol lowering drug lovastatin expired in 2001, Biocon moved into statins and then into the wider class of cholesterol drugs, often through long term supply contracts that gave it a dependable market rather than a single windfall. Statins at one point accounted for more than half of the company's revenue, and the company's revenue rose from about 70 crore rupees in 1998 to about 500 crore rupees in 2004, the year it went public.^[1][11]

Research spending is where Biocon deliberately differs from most Indian drug companies. It directed about ten per cent of its revenue into research and development as of 2014, a far higher proportion than its peers, and it has filed at least 950 patent applications. Between 2005 and 2010 alone it entered into more than 2,200 research licensing and other high value deals, an intensity of deal making that turned a mid sized Indian firm into a partner for much larger multinationals.^[1][11]

Biocon Biologics is the part of the group that makes biosimilars, the follow on versions of complex biologic drugs, and it is now a business in its own right with outside investors. The company's work on insulin and antibody treatments is aimed directly at the affordability problem that first interested her, and it is the reason Biocon's name appears in global debates about the cost of biologic medicine rather than only in Indian ones.^[1]

Syngene, Clinigene and the group companies

• Syngene International, set up in 1994, provides early research and development support services to other drug companies on a contract basis, which gave Biocon a second revenue line that did not depend on its own molecules.^[1]
• Clinigene International, set up in 2000, focused on clinical research trials and the development of generic and new medicines. It was later merged into Syngene.^[1]
• Syngene's listing on the BSE and NSE in 2015 turned the contract research arm into a separately traded company, which at the time of writing had a market capitalisation of about 23,000 crore rupees.^[1]
• Biocon Biopharmaceuticals, incorporated in 1990 with the Cuban Center of Molecular Immunology, was the group's route into biotherapeutics and one of the earliest Indian collaborations of its kind.^[1]

How Biocon built its research base

The research base that separates Biocon from a plain manufacturer was assembled slowly and mostly with borrowed money. She began building an in house research and development team in 1984, working on the discovery of novel enzymes and on techniques for solid substrate fermentation. The company's first major expansion came in 1987, when Narayanan Vaghul of ICICI Ventures supported the creation of a venture capital fund of 250,000 dollars, money she used to build a new plant using a proprietary semi automated tray culture process inspired by Japanese techniques.^[1]

In 1989 Biocon became the first Indian biotechnology company to receive United States funding for proprietary technologies, which was a validation of the science as much as a financial event. By then the company had begun the shift that defined its later shape, from industrial enzymes sold by the tonne to biopharmaceuticals sold by the milligram, where the same fermentation skill produces a far more valuable output.^[1]

The technical bets it placed alongside that shift were specific. It invested in yeast expression platforms on the argument that unicellular methylotrophic yeasts such as Pichia pastoris are a cheaper and more controllable alternative to mammalian cell cultures for producing vaccines, antibody fragments, hormones, cytokines, matrix proteins and biosimilars. It built the largest perfusion based antibody production facilities of their kind in the world, and it became Asia's largest producer of insulin, a product whose economics depend entirely on yield per litre and on scale.^[1]

The diseases it chose were chosen for India rather than for the global market. Because a high proportion of Indians chew betel or tobacco, India accounts for about 86 per cent of the world's oral cancer, known locally as cancer cheek, and because many people do not wear shoes, a minor scrape can become gangrene, the so called diabetes foot. Biocon's programmes in cancer, diabetes, rheumatoid arthritis and psoriasis all sit against that backdrop, and its products include a Pichia derived recombinant human insulin and insulin analogues, an anti EGFR monoclonal antibody for head and neck cancer and a biologic for psoriasis.^[1]

The scale of the effort is best shown by the numbers rather than the adjectives. Biocon directed about ten per cent of its revenue into research and development as of 2014, a much higher proportion than most Indian pharmaceutical companies, it has filed at least 950 patent applications, and between 2005 and 2010 it entered into more than 2,200 high value research licensing and other deals. The last figure is the one that surprises people who think of the business as a maker of cheap copies: most of those agreements were with companies that wanted Indian science inside their own products.^[1][11]

Business career and companies

Her company's ownership changed hands three times before it belonged to her outright, and that history is the mechanism behind the fortune. Biocon Biochemicals of Ireland, founded by Auchincloss, was bought by Unilever in 1989, and the Unilever period gave the Indian company access to global processes and quality systems it could not have bought. In 1997 Unilever sold its specialty chemicals division, including its Biocon shares, to Imperial Chemical Industries.^[1]

In 1998 her fiance, the Scotsman John Shaw, personally raised 2 million dollars to buy the outstanding Biocon shares from ICI. The couple married the same year, she became known as Kiran Mazumdar-Shaw, and John Shaw left his position as chairman of Madura Coats to join the company, becoming Biocon's vice chairman in 2001. The transaction is the single most important business decision in the story after the founding, because it converted a subsidiary of a foreign chemicals group into a company the founding family controlled.^[1]

The decision to list came in 2004, after she sought the advice of Narayana Murthy, the co founder of Infosys, whom she counts among her mentors. Her purpose was to raise capital for Biocon's research programmes, and the listing, the first initial public offering by an Indian biotechnology company, was oversubscribed 33 times; its first day of trading closed with a market value of 1.11 billion dollars, making Biocon the second Indian company to cross the billion dollar mark on its first day.^[1][11]

Beyond her own company she has held a series of public positions, from the chairmanship of the Indian Institute of Management Bangalore to a term on the board of the Massachusetts Institute of Technology and a directorship at Infosys. Those roles matter to the story because they are how a biotech founder in Bengaluru came to sit in the rooms where Indian business policy and higher education are decided.^[1][9]

Net worth and wealth

Her wealth is the value of her stake in the company she built, which means it moves with the Biocon share price rather than with anything she does that year. Forbes put her net worth at about 3.42 billion dollars in 2025, when it ranked her the 93rd wealthiest person in India. That figure is the estimate of one publication on one date, and it has moved widely over the years with the group's share price.^[1][2]

The recognition numbers have moved the same way, and they are worth keeping with their years. Forbes listed her as the 92nd most powerful woman in the world in 2014 and the 85th in 2015, and the 68th in 2019. TIME magazine named her among its 100 most influential people in the world in 2010, and the Financial Times put her on its top 50 women in business list in 2011.^[1][3]

Her giving is measured alongside her wealth in India. The Hurun India Philanthropy List of 2019 placed her 14th for a donation of about 72 crore rupees, equal to roughly 7 million dollars at the time, and ranked her second in its list of women philanthropists for that year. The Hurun ranking is the closest thing Indian business has to a public ledger of large giving, and it is the reason her philanthropy can be compared to her balance sheet at all.^[1][2]

Husband and family

She married John Shaw in 1998. Shaw was a Scottish businessman who had been chairman of Madura Coats, and he gave up that career to join Biocon, where he became vice chairman in 2001 and was described in the Indian press as her partner in the company as well as in life. The two were unusual among Indian business couples in the 1990s for the plainness with which the company credited him with the commercial side of the partnership.^[1]

Shaw died on 24 October 2022. The marriage produced no children, and in her public remarks about philanthropy she has repeatedly returned to the illnesses of the people closest to her rather than to family succession. She and John Shaw were both named in the Pandora Papers, the 2021 leak of offshore financial records, a disclosure that attached to them the usual questions about trusts held outside the country.^[1][7]

The deaths she talks about most are those of her best friend, Nilima Rovshen, and the cancers that struck her husband and her mother. Those losses, rather than any calculation about corporate social responsibility, are the stated reason for the cancer care and diagnostic work that now carries her name.^[1][7]

Personal life

She is a rare thing in Indian business: a founder who says what she thinks in public and takes positions that are not always convenient for her industry. She dislikes the word philanthropy, on the grounds that it usually funds a temporary fix rather than the cause of a problem, and prefers to describe herself as a compassionate capitalist on the argument that a business model which pays for itself keeps working after the grant runs out.^[1]

She writes about business, science and Bengaluru on a personal blog, and her public speaking is more likely to be about the price of a drug or the state of a city than about her own company. Her explanation for the affordable innovation strategy is that a medicine which nobody can afford is not really a medicine, and that the products her company is proudest of are the ones that moved a treatment from a rich patient to a poor one.^[1][12]

Her personal habits are not the subject of much coverage, and she has kept a life outside work that is deliberately small in the telling. What the record shows instead is a working life of unusual length: she has run the same company since 1978, which makes her one of the longest serving founders in Indian industry.^[1]

House and property

She is a Bengaluru person by birth, education and business, and the physical centre of the story is Biocon Park, the campus built in 2005 on 35 hectares outside the city with about 5,000 employees. The park is the answer to a question that runs through every account of the company: how a biotech business with demanding water, power and sterility requirements was built in a country that could not then guarantee any of the three.^[1]

Her first property decision was also the first proof that the company would survive. At the end of her first year of trading she used the earnings to buy an eight hectare site, on the reasoning that a business which intends to expand should own its own ground. The pattern set then, land bought early and built on internally, is visible in the group's continued preference for building its own plants rather than buying them.^[1]

Her residence is in Bengaluru and she has kept it out of the public record, which distinguishes her from several of the industrialists on the same wealth lists who live in buildings the whole country can name. The largest property she is publicly associated with is the one that carries the company name.^[1]

Board memberships and positions

• Founder, executive chairperson and managing director of Biocon Limited, and chairperson of Biocon Biologics.^[1]
• Former chairperson of the board of governors of the Indian Institute of Management Bangalore, which she became in February 2014, the first woman to hold the post.^[1][9]
• Independent director on the board of Infosys.^[1]
• Member of the board of governors of the Indian School of Business, and a past member of the board of governors of the Indian Institute of Technology Hyderabad.^[1]
• Term member of the board of the Massachusetts Institute of Technology in the United States until 2023, and a member of the advisory board of the MIT Jameel Clinic.^[1]
• Member of the advisory board of the Maharashtra State Innovation Society.^[1]
• Member of the Brand Bengaluru Task Force, the state committee on traffic, water supply and waste management that has been working on the city's development blueprint.^[1]

Awards and recognition

• Padma Shri, 1989, and Padma Bhushan, 2005, two of India's highest civilian honours.^[1]
• Othmer Gold Medal, 2014, awarded for contributions to the progress of science and chemistry.^[1]
• Elected to the United States National Academy of Engineering, 2019, for the development of affordable biopharmaceuticals and the biotechnology industry in India; she is the first Indian woman to receive the honour.^[1]
• EY World Entrepreneur of the Year, 2020, an award given to one founder each year across the whole world.^[1]
• Nikkei Asia Prize, 2009, for regional growth, and the Veuve Clicquot Initiative for Economic Development for Asia award, 2007.^[1]
• Ernst and Young Entrepreneur of the Year for life sciences and healthcare, 2002, and recognition as a Technology Pioneer by the World Economic Forum the same year.^[1]
• Honorary doctorates from her own alma mater at Ballarat, and from the University of Abertay Dundee, the University of Glasgow, Heriot Watt University, University College Cork, Davangere University and Concordia University in Montreal.^[1][10]
• Australia's highest civilian honour, awarded in January 2020, which made her the fourth Indian citizen to be recognised in that way.^[1]

Philanthropy

In 2004 she started the Biocon Foundation, the company's social wing, which works in health, education and infrastructure, with a deliberate focus on rural Karnataka. Its best known programme is the Arogya Raksha Yojana, or health protection scheme, developed with Devi Shetty of the Narayana Hrudayalaya hospital group, which sets up clinics that offer clinical care, generic medicines and basic tests to people who cannot otherwise afford them.^[1][8]

The clinics are run on a micro financed health insurance model rather than as charity. Biocon supplies low cost drugs at a negligible margin on each unit and makes its return on volume, and the clinics use a subsidised convenience pricing plan in which wealthier patients pay full price for the convenience of choosing their appointment times while poorer patients pay little or nothing for the less popular slots. As of 2010, seven clinics each served a population of about 50,000 people within a ten kilometre radius, treating more than 300,000 people a year in total.^[1][8]

Cancer is the second pillar, and it is personal. In 2009 she established the Mazumdar Shaw Medical Foundation with a 1,400 bed cancer care centre on the Narayana Health City campus in Bengaluru, again in collaboration with Devi Shetty, and in 2011 she added a centre for advanced therapeutics with a bone marrow transplant unit and a research centre. The foundation is a non profit with two arms, a centre for translational research and a cancer outreach programme.^[1][7][8]

The third strand is smaller and more specific. She has funded the development of a basic mathematics textbook introduced in Kannada schools in 2006, and created the Biocon Cell for Innovation Management at the Indian School of Business in 2009 to support a multi year research programme. In 2015 she joined the Giving Pledge, the public commitment by which signatories promise to give away at least half of their wealth.^[1]

Bengaluru and public life

Bengaluru is the other half of her public life, and she has spent as much time arguing about the city as about the company. She speaks and writes about India's infrastructure gap in terms of governance, job creation and food, water and health insecurity, and her argument is that a city which cannot move its people or supply its industry with water has a growth problem rather than a civic one.^[1]

Her involvement goes back to the Bangalore Agenda Task Force, the initiative of S. M. Krishna and Nandan Nilekani that tried to bring private sector discipline to the city's services. She is part of the Bangalore City Connect Foundation, a non profit trust that discusses civic issues with both urban stakeholders and the government, and she works with the Jana Urban Space Foundation and local government on road improvement. She is also involved with the Bangalore Political Action Committee, known as B.PAC, a non profit that campaigns for better governance and voter participation in the city.^[1]

The commercial argument for that activism is straightforward. Biocon, Infosys and the other large Bengaluru employers have together changed the city from what was once described as a pensioner's paradise into what the same writing now calls the best urban working environment in India, largely by attracting scientists and engineers who would otherwise have gone abroad. Biocon Park, the company's 35 hectare campus with about 5,000 employees, is the physical expression of that, and it is also why she keeps saying that a company's address is a business variable.^[1]

The clearest test of whether the civic rhetoric was real came after the floods of 2009, when Biocon joined Infosys and Wipro in committing to rebuild homes in north Karnataka. Biocon's share was 3,000 houses at a cost of about 30 crore rupees, which is a small number against the group's revenue and a large one against the public response. Her preference for the phrase compassionate capitalist over philanthropist is really a claim about this kind of work: that it should be structured, measurable and connected to a functioning business rather than to sentiment.^[1]

Controversies and criticism

The clearest mark against her name is the Pandora Papers. She and John Shaw were named in the 2021 leak of documents from offshore law firms, which placed them among the Indian business figures whose financial arrangements outside the country became public. The disclosure did not allege illegality, and the usual defence, that such structures are lawful and were used for legitimate reasons, applies; but the publication put a question mark over the gap between a public image built on affordable medicine and the private machinery of a large fortune.^[1]

Her civic role is the second line of criticism. She is a prominent figure in Bengaluru's urban politics through vehicles such as the Bangalore Political Action Committee and the city connect groups that lobby for infrastructure and governance reform, and her closeness to successive state governments is read by supporters as public spiritedness and by critics as the ordinary blurring of corporate and political interest that large Indian companies benefit from.^[1]

The third criticism is aimed at the industry rather than at her personally, and it is the one she answers most directly. Affordable innovation means making medicines available, but it also means defending a patent and pricing strategy inside a system that rewards volume over novelty, and critics of the Indian generics and biosimilars sector argue that the model can reward replication as much as discovery. Her public answer, that a drug no poor patient can afford is not a solution to anything, is a position rather than a proof, and the argument about it is not closed.^[1][12]

Related entries